HTA Database - Search Results

Sort by Relevance

Search Results [1476 Hits] Selected Records [0 Hits] [Clear]

Year	Source	Title
2018	European Network for Health Technology Assessment (EUnetHTA)	Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing
2018	Institute for Clinical Effectiveness and Health Policy (IECS)	[Vitamin D - population screening and supplementation in populations with deficit]
2018	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Blinatumomab (new therapeutic indication: acute lymphatic leukaemia, paediatric patients aged 1 year or older)]
2018	Canadian Agency for Drugs and Technologies in Health (CADTH)	Screening for chlamydia trachomatis and neisseria gonorrhoeae during pregnancy: a health technology assessment
2018	Canary Health Service	[SEEKER System for the screening of lysosomal storage diseases]
2018	Health Information and Quality Authority (HIQA)	Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Invitation and decision aid for cervical cancer screening]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Colorectal cancer screening in persons with a relevant family history - Update to commission S11-01]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for depression]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for hepatitis B]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for hepatitis C]
2018	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for serological group B streptococci within the framework of the medical check-ups according to the maternity Guidelines]
2017	NIHR Health Technology Assessment programme	Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
2017	NIHR Health Technology Assessment programme	Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis
2017	NIHR Health Services and Delivery Research programme	Interventions to improve contact tracing for tuberculosis in specific groups and in wider populations: an evidence synthesis
2017	NIHR Health Services and Delivery Research programme	Incentives in Diabetic Eye Assessment by Screening (IDEAS) trial: a three-armed randomised controlled trial of financial incentives
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bariatric surgery as treatment for obesity in subjects over 65 years old]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	Bariatric surgery to treat obesity in individuals under 21 years old
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Nonmydriatic stereoscopic retinal imaging for retinal condition]
2017	NIHR Health Technology Assessment programme	Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation
2017	NIHR Health Technology Assessment programme	Provision of information about newborn screening antenatally: a sequential exploratory mixed-methods project
2017	HAYES, Inc.	The prostate health index for prebiopsy triage (Beckman Coulter)
2017	HAYES, Inc.	Ketamine infusion for treatment-resistant bipolar depression
2017	HAYES, Inc.	Cologuard (Exact Sciences Corp.)
2017	HAYES, Inc.	Digital breast tomosynthesis for breast cancer diagnosis and screening
2017	Andalusian Health Technology Assessment Area (AETSA)	Multitarget stool DNA testing for colorectal cancer screening.
2017	Norwegian Institute of Public Health (NIPH)	Digital Breast Tomosynthesis with Hologic 3D mammography Selenia Dimensions System for use in breast cancer screening
2017	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: comparison of cervical cancer screening strategies involving the human papillomavirus screening test (HPV test) or gynecological cytology (Pap test)]
2017	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: relevance of introducing a pathogen inactivation process for labile blood products in Quebec]
2017	Institute for Clinical Effectiveness and Health Policy (IECS)	[Cerebrospinal fluid neurotransmitter screening in encephalopathies]
2017	Canadian Agency for Drugs and Technologies in Health (CADTH)	Screening for hepatitis C virus: a systematic review
2017	Andalusian Health Technology Assessment Area (AETSA)	[Neonatal hypoacusis screening]
2017	Health Information and Quality Authority (HIQA)	Health technology assessment of human papillomavirus testing as the primary screening method for prevention of cervical cancer
2017	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Invitation and decision guide for breast cancer screening]
2017	Agency for Healthcare Research and Quality (AHRQ)	Diagnostic accuracy of screening and treatment of post-acute coronary syndrome depression: a systematic review
2017	Canary Health Service	[Early detection of hepatocarcinoma in patients at risk]
2017	Canary Health Service	[Tools for early detection of disease-related malnutrition for adult population in the hospital setting]
2016	NIHR Health Technology Assessment programme	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016	NIHR Health Technology Assessment programme	The natural history of Chlamydia trachomatis infection in women: a multi parameter evidence synthesis
2016	NIHR Health Technology Assessment programme	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2016	NIHR Health Technology Assessment programme	The relationship between pelvic vein incompetence and chronic pelvic pain in women: systematic reviews of diagnosis and treatment effectiveness
2016	NIHR Health Technology Assessment programme	A programme of studies including assessment of diagnostic accuracy of school hearing screening tests and a cost-effectiveness model of school entry hearing screening programmes
2016	NIHR Health Technology Assessment programme	An observational study to assess if automated diabetic retinopathy image assessment software can replace one or more steps of manual imaging grading and to determine their cost-effectiveness
2016	NIHR Health Technology Assessment programme	Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation
2016	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Low-dose computed tomography screening for lung cancer]
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Mutational screening of notch3 gene in the diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukocencephalopathy (CADASIL)
2016	Health Quality Ontario (HQO)	Ultrasound as an adjunct to mammography for breast cancer screening: a health technology assessment
2016	Health Quality Ontario (HQO)	Women's experiences of inaccurate breast cancer screening results: a systematic review and qualitative meta-synthesis
2016	Health Quality Ontario (HQO)	Ultrasound as an adjunct to mammography for breast cancer screening: OHTAC recommendation
2016	HAYES, Inc.	Epi proColon (Epigenomics Inc.)
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Screening, diagnostics and indication for occupational therapy in children and adolescents with Developmental Coordination Disorders]
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Hepatitis C virus screening in hospitals]
2016	Institute of Health Economics (IHE)	Newborn blood spot screening for galactosemia, tyrosiemia type I, homocystinuria, sickle cell anemia, sickle cell/beta-thalassemia, sickle cell/hemoglobin C disease and severe combined immunodeficiency
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation
2016	HAYES, Inc.	Oncotype DX DCIS Breast Cancer Test (Genomic Health Inc.)
2016	HAYES, Inc.	Oncotype DX DCIS breast cancer test (Genomic Health Inc.)
2016	HAYES, Inc.	Oncotype DX Genomic Prostate Score (GPS) Assay (Genomic Health Inc.)
2016	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	[Re-orientation of the Austrian parent-child preventive care programme. Part XII: Economic evaluation of selected screenings during pregnancy]
2016	Penn Medicine Center for Evidence-based Practice (CEP)	Social work support following distress screening in oncology care
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, security and economic evaluation of the screening for cryptorchidism
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Design and validation of a screening tool for evaluating the health impact of regional policies]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Prenatal screening for Down syndrome through fetal DNA sequencing from maternal blood]
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, security and economic evaluation of existing alternatives for monitoring growth and pubertal development
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, security and economic evaluation of existing alternatives for the early detection of hypercholesterolemia in the paediatric population.
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, safety and economic evaluation of existing alternatives for the early detection of childhood hearing impairment
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, safety and economic evaluation of existing alternatives for the early detection of arterial hypertension in paediatric population
2016	Health Sciences Institute in Aragon (IACS)	Early detection program of health problems between the 0 and 14 years. Effectiveness, Safety and Economic Evaluation of the different existent alternatives in the early detection of alterations of psychomotor development
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, safety and economic evaluation of the existing alternatives for the early detection of Attention Deficit Hyperactivity Disorder (ADHD)
2016	Health Sciences Institute in Aragon (IACS)	Early detection program of health problems between the 0 and 14 years. Effectivenes, safety and economic evaluation of the different existent alternatives in the early detection of autism spectrum disorders (ASD)
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, safety and economic evaluation of existing alternatives for the early detection of visual impairment in the paediatric population.
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Parent information on newborn screening using pulse oximetry; addendum to commission S13-01]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for tyrosinaemia type 1 using tandem mass spectrometry]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Information for health insurance fund members on ultrasound screening for abdominal aortic aneurysms: addendum to commission S13-04]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Invitation and decision aid for bowel cancer screening]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Newborn screening for severe combined immunodeficiency (SCID screening)]
2016	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ataluren (expiry of the deadline)]
2016	Canary Health Service	[Fetal DNA analysis in maternal blood for the detection of trisomies 21, 18 and 13]
2016	Canary Health Service	[Safety, clinical effectiveness and cost-effectiveness of stereo-electroencephalography in epilepsy surgery]
2015	NIHR Health Technology Assessment programme	The TOMMY trial: a comparison of TOMosynthesis with digital MammographY in the UK NHS Breast Screening Programme - a multicentre retrospective reading study comparing the diagnostic performance of digital breast tomosynthesis and digital mammography with digital mammography alone
2015	NIHR Health Technology Assessment programme	Screening for psychological and mental health difficulties in young people who offend: a systematic review and decision model
2015	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	[Interventions to improve health-related behaviours of men]
2015	NIHR Health Technology Assessment programme	Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis
2015	NIHR Health Technology Assessment programme	Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening
2015	NIHR Health Technology Assessment programme	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling
2015	NIHR Health Technology Assessment programme	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part III: carnitine uptake deficiency (CUD); short-chain acyl-CoA dehydrogenase deficiency (SCADD); very long-chain acyl-CoA dehydrogenase deficiency (VLCADD)]
2015	NIHR Health Services and Delivery Research programme	Translation into British Sign Language and validation of the Strengths and Difficulties Questionnaire
2015	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Clinical effectiveness of newborn screening for inborn errors of metabolism using mass spectrometry. Part IV: Beta-kethiolase deficiency (BKT); 3-Hydroxy-3-methyl glutaric aciduria (HMG)]
2015	Agency for Healthcare Research and Quality (AHRQ)	Routine iron supplementation and screening for iron deficiency anemia in children ages 6 to 24 months: a systematic review to update the U.S. Preventive Services Task Force Recommendation
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Checking checked: appropriate use of health checks
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Neonatal screening: new recommendations
2015	Health Council of the Netherlands Gezondheidsraad (GR)	Population Screening Act: study of faecal tests within the population based screening programme for colorectal cancer
2015	Agency for Healthcare Research and Quality (AHRQ)	Routine iron supplementation and screening for iron deficiency anemia in pregnant women
2015	Health Quality Ontario (HQO)	Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis
2015	Health Quality Ontario (HQO)	Harms of Prostate-Specific Antigen (PSA) screening in prostate cancer: a rapid review
2015	Health Quality Ontario (HQO)	Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis